Inclusion Criteria:  Must be ≥18 and ≤70 years of age. Must have confirmed diagnosis of AML in first or second complete remission (CR1 or CR2) or have bone marrow blasts ≤10% without circulating blasts. AML sample from the patient must have evidence of CD33 expression (>0%) AML must have intermediate or high-risk disease-related genetics and the presence of minimal residual disease (MRD). Subjects in CR2 or with persistent morphologic blasts; may have favorable disease-related genetics. Candidate for HLA-matched allogeneic HCT using a myeloablative conditioning regimen. Must have a related or unrelated stem cell donor that is a 10/10 match for HLA-A, -B, -C, -DRB1 and -DQB1.  Must have adequate performance status and organ function as defined below:  Performance Status: Karnofsky score of ≥70. Cardiac: left ventricular ejection fraction (LVEF) ≥50% Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO), forced vital capacity (FVC), and forced expiratory volume in one second (FEV1) ≥66%. Renal: estimated glomerular filtration rate (GFR) >60 mL/min Hepatic: total bilirubin <1.5 × ULN, or if ≥1.5 × ULN direct bilirubin <ULN and ALT/AST <1.5 × ULN (per institutional criteria).  Exclusion Criteria:  Prior autologous or allogeneic stem cell transplantation. Presence of the following disease-related genetics: t(15; 17)(q22; q21), or t(9; 22)(q34; q11), or other evidence of acute promyelocytic leukemia or chronic myeloid leukemia. Prior treatment with Mylotarg™ (gemtuzumab ozogamicin). Active central nervous system (CNS) leukemia or history of other active malignancy(ies). Patients diagnosed with Gilbert's syndrome. Uncontrolled bacterial, viral, or fungal infections; or known human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C infection.